Lisanti Capital Growth LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,265 shares of the company's stock after selling 108,445 shares during the quarter. Lisanti Capital Growth LLC owned about 0.17% of Castle Biosciences worth $1,233,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in Castle Biosciences by 147.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company's stock valued at $4,719,000 after purchasing an additional 98,571 shares during the last quarter. Barclays PLC lifted its stake in shares of Castle Biosciences by 310.7% in the 3rd quarter. Barclays PLC now owns 52,301 shares of the company's stock valued at $1,491,000 after purchasing an additional 39,567 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Castle Biosciences by 165.2% during the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock worth $1,980,000 after buying an additional 43,241 shares during the period. GSA Capital Partners LLP acquired a new stake in Castle Biosciences in the 3rd quarter valued at $1,478,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Castle Biosciences by 16.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company's stock worth $7,836,000 after purchasing an additional 39,417 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
Castle Biosciences Stock Performance
CSTL stock traded up $0.61 during trading on Tuesday, hitting $19.54. 735,986 shares of the company's stock traded hands, compared to its average volume of 474,652. The stock has a market capitalization of $547.26 million, a price-to-earnings ratio of 97.70 and a beta of 0.98. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The stock has a fifty day moving average price of $26.46 and a two-hundred day moving average price of $28.90. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on CSTL. Robert W. Baird upped their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences currently has an average rating of "Buy" and an average target price of $40.00.
Read Our Latest Stock Report on Castle Biosciences
Insider Buying and Selling at Castle Biosciences
In related news, insider Derek J. Maetzold sold 2,130 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the transaction, the insider now owns 78,335 shares in the company, valued at $1,529,099.20. The trade was a 2.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the transaction, the director now owns 1,425 shares of the company's stock, valued at approximately $41,524.50. The trade was a 84.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,568 shares of company stock worth $1,321,364 over the last ninety days. Company insiders own 7.20% of the company's stock.
Castle Biosciences Profile
(
Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Articles
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
